Alaska Air Group, Inc.
$9.77B- Market cap
- $4.55B
- Debt
- +$5.85B
- Cash
- −$627.00M
Capital structure 44% equity / 56% debt · EV / Revenue 0.69x · EV / EBITDA 19.31x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALK stock price vs ALNY: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Implied fair value · at ALK's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALK FY 2025 (ended Dec 31, 2025) · ALNY FY 2025 (ended Dec 31, 2025).
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 44% equity / 56% debt · EV / Revenue 0.69x · EV / EBITDA 19.31x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALASKA AIR GROUP, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
1.42x
5.22x
Net debt / EBITDA
Leverage against operating earnings
10.32x
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
$627.00M
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
DELTA AIR LINES, INC.
ALK vs DAL
American Airlines Group Inc.
ALK vs AAL
SOUTHWEST AIRLINES CO
ALK vs LUV
JETBLUE AIRWAYS CORP
ALK vs JBLU
Allegiant Travel CO
ALK vs ALGT
Moderna, Inc.
ALK vs MRNA
Sarepta Therapeutics, Inc.
ALK vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALK vs VRTX
BioNTech SE
ALK vs BNTX
ACADIA PHARMACEUTICALS INC
ALK vs ACAD
$5.85B
$4.12B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.